SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Profiling Reveals Multi-Cellular and Molecular Dysregulation in Alzheimer's Disease Brain

This report details single-cell RNA sequencing findings from human brain tissue, comparing Control, E280A (familial Alzheimer's), and Sporadic Alzheimer's conditions. We observed significant shifts in cellular composition, particularly within microglial populations, alongside profound alterations in cell-cell communication, especially involving extracellular matrix remodeling and synaptic adhesion. Pathway enrichment analyses further highlighted neuronal synaptic dysfunction, robust microglial activation, and impaired oligodendrocyte myelination, collectively revealing a complex multi-cellular pathology in Alzheimer's disease.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Type and Condition Distribution in Brain scRNA-seq Data
2. Major Cell Type Score and Annotation on UMAP Embedding
3. Cell Type Subset Marker Expression Analysis and Annotation Validation
4. Minor Cell Type Population Analysis Across Brain Conditions
5. Microglial Subset Population Shifts in Alzheimer's Disease Conditions
6. Microglial Subset Population Shifts Across Disease Conditions
7. Cell-Cell Interaction Analysis Across Alzheimer's Disease Conditions
8. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease
9. Condition-Specific Surfaceome Markers in Microglia
10. Cell-Type Specific Surfaceome Markers in Human Brain
11. Gene Ontology (GSA) Analysis of Upregulated Pathways in Neurons and Microglia in Alzheimer's Disease Context
12. Gene Set Enrichment Analysis Reveals Cell-Type-Specific Pathway Dysregulation in Brain Conditions
13. Discussion
14. Query List

0. Dataset overview

Dataset Summary

• Data Type: Single-cell RNA-seq data, processed by SCODA into an AnnData object.
• Dimensions: Contains 43,743 cells and 26,318 genes.
• Species & Tissue: Human brain tissue.
• Conditions: Data is categorized under three conditions: E280A, Control, and Sporadic.

Cell Type Annotations:

• Major Cell Types: Neuron, Oligodendrocyte, Astrocyte, Microglia, Endothelial cell, Stromal cell, unassigned.
• Minor Cell Types: Neuron, Oligodendrocyte progenitor cell, Astrocyte, Oligodendrocyte, Microglia, Endothelial cell, Smooth muscle cell, Fibroblast, unassigned.
• Subset Cell Types: Various detailed cell states like Neuron (Glutamatergic), Microglia (M0), Oligodendrocyte (Mature, Myelinating), etc.

Available Precomputed Results:

• Cell-Cell Interaction (CCI) results from CellPhoneDB, available per condition (uns['CCI']) and per sample (uns['CCI_sample']).
• Differential Expression Gene (DEG) results for each celltype_minor comparing one condition vs. the rest (uns['DEG']).
• Gene Set Enrichment Analysis (GSEA) results for each celltype_minor comparing one condition vs. the rest (uns['GSEA']).
• Gene Ontology (GO/GSA) results for each celltype_minor comparing one condition vs. the rest (uns['GSA_up']).

1. UMAP Visualization of Cell Type and Condition Distribution in Brain scRNA-seq Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) visualizations of single-cell RNA sequencing data from human brain tissue. The plots illustrate the distribution of 43,743 cells based on their transcriptional profiles, colored by condition (Control, E280A, Sporadic), individual sample, celltype_major, celltype_minor, and highly resolved celltype_subset. These visualizations are crucial for assessing data quality, validating cell type annotations, and identifying potential shifts in cellular composition or states related to different conditions.

Visual Summary

The UMAPs provide a comprehensive overview of the dataset's structure and cell type heterogeneity:

• Overall Embedding Structure: The UMAP shows a complex but well-structured embedding with several distinct, cohesive clusters, indicating successful dimensionality reduction and preservation of biological relationships between cells. The presence of clear boundaries between major cell types suggests a robust clustering and annotation process.

Condition Distribution:

• The "condition" UMAP reveals that cells from different conditions (Control, E280A, Sporadic) are largely interspersed throughout the main cellular compartments. This indicates a good level of integration, suggesting that the primary clustering is driven by biological cell type identity rather than strong technical batch effects related to the condition groups.
• However, there are noticeable enrichments: the E280A condition (light yellow) shows a more pronounced presence in certain smaller, distinct clusters, and Sporadic samples (dark blue) also appear somewhat enriched in specific regions, particularly within the larger neuronal and oligodendrocyte clusters. This suggests that while cell types are shared, there may be condition-specific cellular states or shifts in cell proportions within certain populations.

Sample Distribution:

• The "sample" UMAP demonstrates a good mixing of individual samples across most major cell clusters. This is a positive indicator, suggesting that potential batch effects from individual samples are largely minimized or accounted for, and that the observed variations are more likely due to biological differences rather than technical artifacts.

Cell Type Major/Minor/Subset Annotation Quality:

• celltype_major: This UMAP clearly delineates major cell types found in the brain: distinct clusters are observed for Neurons, Oligodendrocytes, Astrocytes, Microglia, Endothelial cells, and Stromal cells. The "unassigned" cells form a very small, isolated cluster, which is ideal, indicating minimal ambiguously classified cells broadly scattered across the UMAP.
• celltype_minor: Provides a finer resolution, further distinguishing Oligodendrocyte progenitor cells from mature Oligodendrocytes, and identifying Fibroblasts and Smooth muscle cells within the broader Stromal cell category. These minor types maintain distinct, coherent clusters, confirming higher-resolution annotation quality.
• celltype_subset: This plot showcases remarkable cellular heterogeneity. Neurons are subdivided into numerous specific subtypes (e.g., Glutamatergic, GABAergic, Dopaminergic, Cholinergic, etc.), reflecting the functional diversity of neurons in the brain. Microglia are resolved into distinct activation states (M0, M1, M2a, M2b, M2c), which is highly relevant for studying neuroinflammation. Oligodendrocytes are further classified into Immature, Precursor, and Mature (Myelinating/Non-Myelinating) stages, indicating developmental and functional states. Endothelial cells also show subtypes like tip cells and lymphatic cells. The clear separation of these subsets within their broader categories confirms the high granularity and quality of the cell type annotations.

Biological Interpretation

The detailed UMAP visualizations provide key biological insights into the cellular landscape of the human brain samples:

• Brain Cell Type Diversity: The identification of a wide array of neuronal and glial subtypes, along with vascular and stromal components, accurately reflects the known cellular complexity of brain tissue. This comprehensive cell type map is fundamental for studying brain physiology and pathology. Reference: GeneCards Human Brain Cell Types Search
• Microglial Activation States and Neuroinflammation: The presence of distinct microglial subtypes (M0, M1, M2a, M2b, M2c) is particularly significant. M1 microglia are generally associated with pro-inflammatory responses, while M2 subtypes (M2a, M2b, M2c) are typically involved in anti-inflammatory, reparative, or immunoregulatory functions. Given that the conditions include E280A (often associated with familial Alzheimer's disease) and Sporadic forms, understanding the distribution and prevalence of these microglial states across conditions will be critical for deciphering the role of neuroinflammation in these diseases. Shifts in these populations could indicate differential immune responses or disease progression. Reference: PubMed search for Microglial M1 M2 Alzheimer's
• Neuronal Subtype Specificity: The extensive characterization of neuronal subtypes (e.g., glutamatergic, GABAergic, dopaminergic) allows for investigations into how specific neuronal populations are affected in E280A and Sporadic conditions. Different neurodegenerative diseases often selectively target specific neuronal populations.
• Oligodendrocyte Maturation and Myelination: The identification of different oligodendrocyte stages (precursor, immature, mature myelinating/non-myelinating) provides a valuable framework for studying myelin health and pathology. Demyelination or dysregulation of oligodendrocyte function is implicated in various neurological disorders.
• Condition-Specific Cellular Profiles: While overall cell type composition appears broadly consistent across conditions, the subtle enrichments of E280A and Sporadic cells in specific UMAP regions suggest that these conditions might induce specific transcriptional changes or alter the proportions of certain cell subtypes. This warrants further differential expression and cell proportion analyses to pinpoint disease-relevant cellular changes.

Annotation Notes

The high resolution and clear segregation of celltype_major, celltype_minor, and celltype_subset annotations on the UMAPs indicate excellent quality in the cell type identification and labeling. The presence of only a small, confined "unassigned" cluster further reinforces the robustness of the annotation pipeline. The observed mixing of samples and conditions within major cell types, combined with subtle condition-specific enrichments, suggests a well-integrated dataset suitable for comparative analyses, minimizing the concern of batch effects confounding biological interpretation.

2. Major Cell Type Score and Annotation on UMAP Embedding

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell types within the single-cell RNA-seq dataset on a UMAP (Uniform Manifold Approximation and Projection) embedding. Specifically, it displays a "HiCAT_major_score" for each predefined major cell type (Endothelial cell, Stromal cell, Microglia, Neuron, Astrocyte, Oligodendrocyte), representing the confidence or enrichment of marker gene expression for that cell type across all cells. The final UMAP plot shows the assigned celltype_major annotations for each cell, allowing for a direct comparison and validation of the clustering with the cell type-specific scores.

Visual Summary

The UMAP plots effectively demonstrate the distinct clustering of major cell populations based on their transcriptional profiles.

• Cell Type Specificity: Each "HiCAT_major_score" plot shows clear, localized regions of high scores (indicated by brighter yellow/green colors) corresponding to specific clusters on the UMAP. For example, high scores for "Oligodendrocyte" are concentrated in a large cluster on the right, while "Neuron" scores are prominent in extensive interconnected clusters on the lower-left and middle.
• Concordance with Annotation: The distribution of high scores for each major cell type (e.g., Endothelial cell, Stromal cell, Microglia, Neuron, Astrocyte, Oligodendrocyte) precisely aligns with the corresponding colored regions in the final celltype_major UMAP plot. This strong concordance indicates that the cell type assignments are well-supported by the underlying gene expression patterns.
• Distinct Separation: The major cell types form largely distinct and well-separated clusters on the UMAP, with minimal overlap in their high-scoring regions. This suggests a robust clustering and annotation of the primary cell populations in the brain tissue.
• "unassigned" Cluster: A small cluster labeled "unassigned" is visible, typically indicating cells that do not strongly fit any of the predefined major cell type profiles.

Biological Interpretation

The clear visualization of major cell type scores and their alignment with the final cell type annotations provides strong evidence for the quality and reliability of the cell type identification in this single-cell RNA-seq dataset from human brain tissue.

• Robust Cell Identification: The distinct localization of high scores for each major cell type (e.g., Neuron, Oligodendrocyte, Astrocyte, Microglia, Endothelial cell, Stromal cell) confirms that these cell populations possess unique and well-defined transcriptional signatures, enabling accurate assignment. This is crucial for downstream analyses, especially when studying neurodegenerative conditions like E280A, Control, and Sporadic forms, where cell type-specific changes are highly relevant.
• Expected Brain Cell Composition: The identified cell types—neurons as the primary signaling cells, oligodendrocytes for myelination, astrocytes for support, microglia as immune cells, and endothelial/stromal cells forming the vasculature and connective tissue—represent the fundamental cellular constituents of the human brain. Their presence and relative abundance in the UMAP reflect a comprehensive sampling of the brain tissue.
• Foundation for Differential Analysis: This robust cell type annotation serves as a critical foundation for subsequent analyses, such as differential gene expression (DEG), gene set enrichment analysis (GSEA), and cell-cell interaction (CCI) studies, which are often performed on a cell type-specific basis to uncover disease-relevant mechanisms in the context of the provided conditions. Reliable cell type calls ensure that any observed differences are truly cell type-specific rather than an artifact of mixed cell populations.
• Potential for Further Granularity: While major cell types are clearly defined, the large neuronal cluster, for instance, often encompasses diverse neuronal subtypes (e.g., Glutamatergic, GABAergic, Dopaminergic, as indicated in celltype_subset in the data context). The clear separation at the major cell type level sets the stage for exploring these finer-grained distinctions.

Annotation Notes

The consistency between the HiCAT major cell type scores and the celltype_major UMAP annotations indicates a high degree of confidence in the cell type assignments. The major cell types are well-separated and distinct, suggesting that the clustering and annotation process has successfully resolved the primary cellular identities within the dataset. The presence of an "unassigned" category also indicates a conservative approach, where cells lacking clear markers for major types are appropriately flagged. This robust annotation is essential for drawing accurate biological and medical conclusions from the subsequent, more detailed analyses.

3. Cell Type Subset Marker Expression Analysis and Annotation Validation

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker gene expression dot plot for various celltype_subset categories identified from single-cell RNA-seq data of human brain tissue. The purpose of this visualization is to validate the assigned cell type annotations by examining the expression patterns of their respective marker genes. Each dot represents a gene-cell type pair, with dot size indicating the fraction of cells in that group expressing the gene, and color intensity representing the mean expression level of the gene within the group. The markers shown were selected based on their specificity and expression characteristics across cell types, focusing on surfaceome genes.

Visual Summary

The dot plot effectively illustrates distinct expression profiles for most celltype_subset annotations, indicating well-resolved cell identities.

• Astrocyte cells are clearly distinguished by canonical markers such as *GFAP*, *SLC1A2*, *SLC1A3*, *AQP4*, and *GLUL*, showing high expression and broad detection across cells within this group.
• Endothelial tip cells show specific expression of genes like *DLL4* and *ANGPT2*, consistent with their role in angiogenesis.
• Fibroblasts are characterized by extracellular matrix-related genes, including *DCN*, *COL1A2*, *FBLN1*, and *COL6A2*.

Microglial subtypes exhibit distinct marker sets

• Microglia (M0) express general microglial markers such as *AIF1* (IBA1), *TMEM119*, *PTPRC* (CD45), *MERTK*, *P2RY12*, and *CX3CR1*.
• Microglia (M2b) display enriched expression of *CD86* and *IL1B*, suggesting a specific activated microglial state.
• Microglia (M2c) show robust expression of markers like *MSR1* (CD204), *IL4R*, *CD163*, *SCARB1*, and *TGFB1*, indicative of an anti-inflammatory and reparative phenotype.
• Neuronal subtypes are highly differentiated based on neurotransmitter-associated genes:
• Adrenergic neurons express *DBH* and *SLC6A2*.
• Cholinergic neurons show high levels of *ACHE* and *SLC5A7*.
• Dopaminergic neurons are identified by *TH*, *SLC6A3*, and *DDC*.
• GABAergic neurons express *GAD1*, *GAD2*, *SLC6A1*, and *GABBR1*.
• Glutamatergic neurons are marked by *SLC17A7*, *SLC17A6*, *GRIN1*, and *GRIN2B*.
• Glycinergic neurons express *GLS* and *SLC6A9*.
• Noradrenergic neurons are primarily marked by *DBH*.

Oligodendrocyte lineage cells also show clear differentiation

• Oligodendrocyte progenitor cells (OPCs) express *PDGFRA*, *SOX10*, *OLIG1*, and *CSPG4*.
• Oligodendrocyte (Mature, Myelinating) cells exhibit high expression of key myelin components such as *MBP*, *MOG*, *PLP1*, and *MAG*.
• Oligodendrocyte (Mature, Non-Myelinating) cells are characterized by markers like *ERMN* and shared expression of some mature oligodendrocyte genes, distinguishing them from the myelinating subtype.
• Smooth muscle cells are identified by canonical markers like *ACTA2*, *TAGLN*, *MYH11*, and *TPM2*, consistent with vascular smooth muscle in the brain.

Red boxes visually group the most specific markers for each cell type, reinforcing the uniqueness of their expression profiles.

Biological Interpretation

The observed marker gene expression patterns strongly support the biological identities assigned to each celltype_subset. The human brain is a complex organ comprising a diverse array of cell types, and single-cell RNA sequencing allows for the resolution of this heterogeneity.

• Glial Cells: Astrocytes are crucial for brain homeostasis, synaptic support, and neuroprotection, and their identified markers (*GFAP*, glutamate transporters, *AQP4*) reflect these roles PubMed: 30046187. Microglial subsets, including M0 (resting/general), M2b, and M2c (associated with tissue repair and immunomodulation), indicate the intricate immune surveillance and response mechanisms within the brain, which can be critical in neurodegenerative diseases like those represented by the 'E280A' and 'Sporadic' conditions PubMed: 32094892. The clear distinction of oligodendrocyte lineage cells—from progenitor cells (OPCs) to mature myelinating and non-myelinating oligodendrocytes—highlights the dynamic process of myelination and its maintenance, fundamental for neural communication PubMed: 30206152.
• Neuronal Diversity: The fine-grained resolution of distinct neuronal subtypes based on their neurotransmitter synthesis and receptor profiles (e.g., dopaminergic, GABAergic, glutamatergic) is critical for understanding specific neural circuits and their dysfunction in neurological disorders. For example, dopaminergic neurons are central to movement control and reward, while GABAergic and glutamatergic neurons are the primary inhibitory and excitatory neurons, respectively.
• Vascular Components: The presence and specific markers for endothelial tip cells and smooth muscle cells confirm the capture of essential vascular components within the brain tissue sample, which are vital for blood-brain barrier function and nutrient supply.

The selection of surfaceome markers in the analysis configuration is particularly valuable. Surface proteins are often key for cell-cell communication and are accessible for experimental manipulation or cell isolation techniques, further enhancing the utility of these markers for downstream biological validation.

Annotation Notes

The marker expression dot plot provides strong evidence validating the celltype_subset annotations. Each cell type displays a highly specific and characteristic set of marker genes, which aligns well with known biological functions and identities in the human brain. This robust separation and clear marker specificity suggest high confidence in the current clustering and annotation scheme. No significant issues with ambiguous markers or poor cluster definition are apparent, reinforcing the quality of the single-cell data processing and annotation.

4. Minor Cell Type Population Analysis Across Brain Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot showing the proportional distribution of minor cell types across individual samples from Control, E280A (likely familial Alzheimer's disease), and Sporadic (likely sporadic Alzheimer's disease) conditions. The goal is to visualize potential shifts in cellular composition associated with these distinct conditions, providing an initial overview of brain cellular landscape alterations.

Visual Summary

The stacked bar plot effectively illustrates the relative abundance of nine minor cell types (Astrocyte, Endothelial cell, Fibroblast, Microglia, Neuron, Oligodendrocyte, Oligodendrocyte progenitor cell, Smooth muscle cell, unassigned) within each sample, grouped by condition.

• Dominant Cell Type: Neurons (light yellow) are consistently the most abundant cell type across all samples and conditions, as expected for brain tissue. Their proportion generally ranges from 70% to 90%.
• Control Samples: The cellular proportions within the control group appear relatively stable across individual samples. Neurons are predominantly followed by Oligodendrocytes, Microglia, Astrocytes, and Endothelial cells, in decreasing order of abundance.

E280A Samples

• A notable observation is the presence of a substantial "unassigned" cell population (blue bar) in sample E280A 7, which is not prominent in other samples. This might indicate issues with cell type assignment for this specific sample or a unique cell state.
• Compared to controls, some E280A samples (e.g., E280A 2, 4, 1, 3) exhibit a slightly increased proportion of Astrocytes (dark red) and Microglia (orange), suggesting an inflammatory or reactive glial response.

Sporadic Samples

• Similar to E280A, Sporadic samples (e.g., Sporadic 8, 1, 2, 6) often show a more pronounced increase in the relative proportions of Astrocytes (dark red) and Microglia (orange) compared to controls. This trend appears somewhat more widespread and potentially larger in magnitude across multiple sporadic samples than in E280A.
• There is also some variability in the representation of Fibroblasts (light orange) and Endothelial cells (red) across sporadic samples.

Biological Interpretation

Given the context of human brain tissue and conditions like E280A and Sporadic (strongly indicative of Alzheimer's disease based on AnnData metadata like BRAAK, CERAD, NIA.AA scores), the observed shifts in cell type proportions offer significant biological insights:

• Evidence of Neurodegeneration and Gliosis: The brain in Alzheimer's disease (AD), both familial (like E280A) and sporadic forms, is characterized by progressive neuronal loss PubMed Search: neuronal loss Alzheimer's disease. While neurons remain the most abundant cells, a relative decrease in neuronal proportion, often accompanied by a relative increase in glial cell populations, is a common feature. This is consistent with the general pattern seen, where Astrocytes and Microglia appear to constitute a larger fraction in disease states.
• Astrocyte and Microglial Activation: The increased relative proportions of Astrocytes and Microglia in E280A and, more prominently, in Sporadic samples, strongly suggest ongoing neuroinflammation and reactive gliosis.
• Astrogliosis: Astrocytes become reactive in response to neuronal injury and pathological protein accumulation (e.g., amyloid plaques, tau tangles) in AD, forming a glial scar and releasing inflammatory mediators PubMed Search: astrogliosis Alzheimer's disease.
• Microglial Activation: Microglia, the brain's resident immune cells, are activated in AD, attempting to clear amyloid-beta, but can also contribute to chronic inflammation and neuronal damage PubMed Search: microglial activation Alzheimer's disease. The variability in microglial proportions across disease samples could reflect different stages or severities of neuroinflammatory responses.
• Other Cell Types: While less dramatically altered, changes in Endothelial cells, Smooth muscle cells, and Fibroblasts could point to cerebrovascular dysfunction or blood-brain barrier compromise, which are also implicated in AD pathogenesis PubMed Search: blood brain barrier Alzheimer's disease.
• "Unassigned" Cells: The significant "unassigned" population in E280A 7 warrants further investigation. It could represent technical artifacts, cells with low RNA content, or potentially novel/unusual cell states that were not captured by existing annotation references, which might be particularly relevant in a disease context.

Clinical or Translational Implications

The observed shifts in cell type populations, particularly the relative increases in astrocytes and microglia in E280A and Sporadic conditions, have several clinical and translational implications:

• Biomarkers of Disease Progression: Changes in glial cell proportions could serve as potential cellular biomarkers reflecting disease presence, stage, or severity. Further quantitative analysis and correlation with clinical metadata (e.g., NIA.A.A.SCORE, BRAAK, CERAD) would be crucial to establish this.
• Therapeutic Targets: The enhanced presence of reactive astrocytes and activated microglia highlights these cell types as key players in AD pathogenesis. Modulating the activity or abundance of these cells (e.g., through anti-inflammatory therapies or targeting specific glial activation pathways) represents a significant area for therapeutic intervention in both familial and sporadic forms of AD.
• Disease Heterogeneity: The variability in cell type proportions among samples within the E280A and Sporadic groups suggests significant individual heterogeneity in the cellular response to disease. Understanding this variability could lead to more personalized treatment strategies.
• Data Quality Assessment: The presence of "unassigned" cells in one E280A sample emphasizes the importance of quality control and thorough annotation. Resolving these "unassigned" cells could uncover novel cell states or provide insights into unique patient responses.

5. Microglial Subset Population Shifts in Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the proportional distribution of different microglial subsets (M0, M1, M2a, M2b, M2c) across individual samples, grouped by three conditions: Control, E280A (familial Alzheimer's disease), and Sporadic (sporadic Alzheimer's disease). The celltype_subset annotation was used to categorize microglia into these distinct states, providing insight into the microglial activation landscape in the human brain under different disease contexts.

Visual Summary

The stacked bar plot effectively illustrates the relative abundance of microglial subsets within each sample.

• Control Samples: Predominantly composed of Microglia (M0) (deep red), typically accounting for over 80-90% of the total microglia population. Microglia (M2c) (teal) is present in some control samples, constituting a smaller but noticeable fraction (up to ~20%), while M1, M2a, and M2b subsets are largely negligible.
• E280A Samples: Show a more varied distribution compared to controls. While Microglia (M0) remains the most abundant subset, its proportion is generally lower than in controls, ranging from approximately 60% to over 90%. Microglia (M2c) is consistently present and often comprises a larger fraction (up to 30-40%) than in control samples. Microglia (M2a) (light yellow) and (M2b) (light green) show a subtle increase in presence, although still forming minor components. Microglia (M1) (orange) remains very low or absent.
• Sporadic Samples: Exhibit the most pronounced shifts in microglial populations. The proportion of Microglia (M0) is markedly reduced compared to both Control and E280A groups, particularly in some samples (e.g., "Sporadic 5" with ~30-40% M0). Conversely, Microglia (M2c) shows a substantial increase, becoming a major component in several sporadic samples and, in some cases, even surpassing the M0 proportion. Microglia (M2a) and (M2b) also appear slightly more prominent than in the other conditions, although M1 remains consistently very low.

Biological Interpretation

Microglia are the brain's resident immune cells, and their activation state is critical in neurodegenerative diseases like Alzheimer's. The observed shifts in microglial subsets suggest a dynamic response to the pathological environment.

• Shift from Homeostatic (M0) to Activated States: The reduction in Microglia (M0) from Control to E280A, and even more so in Sporadic cases, indicates a deviation from a resting or homeostatic microglial state in Alzheimer's disease. This suggests a general activation or re-polarization of microglia in response to disease pathology.
• Prominent M2c Polarization in Alzheimer's Disease: A key observation is the progressive increase in Microglia (M2c) from Control to E280A, and most notably in Sporadic Alzheimer's disease. M2c microglia are generally associated with anti-inflammatory responses, immunosuppression, phagocytosis of cellular debris, and tissue repair PubMed search: M2c microglia function brain. This could represent an attempt by the brain to clear amyloid-beta plaques or tau tangles, or to resolve chronic inflammation. However, persistent or dysregulated M2c activation might also contribute to an immunosuppressive environment that hinders effective pathogen clearance or fosters disease progression.
• Limited M1 (Pro-inflammatory) Response: The consistently low proportions of Microglia (M1) across all conditions, including disease states, are noteworthy. M1 microglia are typically characterized by a pro-inflammatory phenotype and are often implicated in neurotoxicity PubMed search: M1 microglia neuroinflammation. The absence of a strong M1 signature in this dataset could imply that the primary microglial response in these Alzheimer's brain samples is not dominated by classical pro-inflammatory activation, or that the specific markers used to define M1 in this annotation capture only a minor aspect of the inflammatory response. It's possible that inflammatory processes occur via other microglial states or are transient and localized.
• Subtle Increase in M2a/M2b: The slight increase in M2a and M2b subsets in disease conditions further supports a general shift towards alternative activation states. M2a microglia are involved in wound healing and tissue repair, while M2b microglia are thought to bridge M1 and M2 functions, sometimes involved in antigen presentation and immune regulation GeneCards: CD206 (M2a marker), PubMed search: M2b microglia brain.
• Heterogeneity Across Samples: The notable variability in microglial populations among individual samples within the E280A and Sporadic conditions highlights the heterogeneous nature of Alzheimer's disease pathology and response, even within genetically similar or sporadic cases.

Clinical or Translational Implications

The observed shifts in microglial populations carry significant clinical and translational implications for Alzheimer's disease research.

• Therapeutic Targeting of Microglial States: The differential distribution of microglial subsets, particularly the increase in M2c, suggests that therapeutic strategies aimed at modulating microglial polarization could be beneficial. For example, enhancing beneficial M2c functions (e.g., efficient phagocytosis of pathology) or rebalancing microglial phenotypes to a more protective state could be explored PubMed search: microglia polarization Alzheimer's therapy.
• Biomarker Development: The changes in the proportions of specific microglial subsets, especially M0 and M2c, could potentially serve as biomarkers for disease progression or therapeutic response in different forms of Alzheimer's disease.
• Understanding Disease Mechanisms: These findings underscore that Alzheimer's disease involves a complex and varied microglial response that moves beyond a simple M1 pro-inflammatory activation. Further investigation into the specific roles of M2c microglia in both familial (E280A) and sporadic AD is crucial to determine if this polarization is adaptive, maladaptive, or a failed compensatory mechanism.
• Patient Stratification: The inter-sample variability suggests that microglial responses might differ among individuals with AD. This supports the need for personalized medicine approaches that consider an individual's specific immune profile to optimize treatment strategies.

6. Microglial Subset Population Shifts Across Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional representation of different microglial subsets (M0, M2b, M2c) within the overall microglial population across three conditions: Sporadic (likely Sporadic Alzheimer's Disease), E280A (a familial form of Alzheimer's disease due to a specific PSEN1 mutation [NCBI]), and Control. Box plots illustrate the distribution of these proportions, and statistical comparisons (p-values) highlight significant differences between conditions.

Visual Summary

The box plots present the celltype proportion for three microglial subsets: Microglia (M0), Microglia (M2b), and Microglia (M2c), across Sporadic, E280A, and Control conditions.

Microglia (M0):

• The proportion of Microglia (M0) is significantly higher in Control samples compared to E280A samples (p ≤ 0.05).
• There is no significant difference between Sporadic and E280A (p = 0.13), nor between Sporadic and Control (p = 0.13), though Control shows a trend towards a higher proportion than Sporadic.
• Control samples consistently show the highest median proportion of M0 microglia, followed by E280A and then Sporadic.

Microglia (M2b):

• The proportion of Microglia (M2b) is significantly higher in Sporadic samples compared to Control samples (p ≤ 0.05).
• No significant differences are observed between Sporadic and E280A (p = 0.38) or between E280A and Control (p = 0.10), although Sporadic generally shows a higher median and range than E280A, and E280A shows a higher median than Control.

Microglia (M2c):

• No statistically significant differences in the proportion of Microglia (M2c) are observed between any of the compared conditions (p-values of 0.23, 0.10, and 0.31 for Sporadic vs. E280A, Sporadic vs. Control, and E280A vs. Control, respectively).
• Sporadic samples tend to have a slightly higher median proportion of M2c compared to E280A and Control, but this trend does not reach statistical significance.

Biological Interpretation

Microglia are the primary immune cells of the central nervous system, playing crucial roles in brain homeostasis and pathology. They exhibit diverse functional states, often broadly categorized as 'pro-inflammatory' (M1-like) or 'anti-inflammatory/pro-resolving' (M2-like). The M0 state often represents a quiescent or resting state, but can also encompass an early activation or unpolarized state. M2b microglia are associated with immune regulation, antigen presentation, and can have both pro- and anti-inflammatory properties depending on the context [NCBI]. M2c microglia are generally linked to tissue repair, phagocytosis, and anti-inflammatory responses [NCBI].

Our findings suggest specific alterations in microglial subset proportions in disease conditions (Sporadic and E280A Alzheimer's Disease) compared to healthy controls within the brain tissue:

• Reduced M0 Microglia in E280A AD: The significantly lower proportion of M0 microglia in E280A patients compared to controls may indicate a shift away from a homeostatic or unpolarized state in familial Alzheimer's disease. This could suggest a chronic activation or polarization of microglia in E280A AD, even if not explicitly to M1 or M2 states, implying a sustained engagement in disease-related processes.
• Elevated M2b Microglia in Sporadic AD: The increased proportion of M2b microglia in Sporadic AD compared to controls is a notable finding. M2b microglia are implicated in immune regulation and antigen presentation, and their upregulation could point to specific pathways of immune response or dysregulation in sporadic forms of the disease. This could involve altered responses to amyloid-beta plaques or neurofibrillary tangles, or distinct inflammatory mediators, contributing to disease pathology or attempting to clear debris [NCBI]. This specific polarization might indicate a distinct immune phenotype in Sporadic AD compared to the genetic E280A form.
• Consistent M2c Proportions: The lack of significant change in M2c microglia proportions suggests that the overall capacity for repair, debris clearance, or anti-inflammatory resolution pathways (represented by M2c) may not be proportionally altered between these disease conditions and controls at this level of resolution, or perhaps M2c plays a less prominent *proportional* role in differentiating these conditions compared to M0 and M2b.

These observed shifts highlight distinct microglial responses or pathologies between familial (E280A) and sporadic forms of Alzheimer's disease, as well as compared to healthy controls.

Clinical or Translational Implications

The differential shifts in microglial subset proportions hold potential clinical and translational implications:

• Biomarker Potential: The distinct microglial profiles, particularly the reduced M0 in E280A AD and elevated M2b in Sporadic AD, could serve as potential biomarkers for differentiating disease subtypes or monitoring disease progression. Further validation using larger cohorts and integration with clinical data would be necessary.
• Therapeutic Targeting: Understanding the specific polarization states prevalent in different AD conditions could guide the development of targeted immunomodulatory therapies. For instance, in Sporadic AD, therapies aiming to modulate M2b-associated pathways might be considered. Conversely, understanding why M0 is reduced in E280A AD could inform strategies to restore microglial homeostasis. Modulating microglial states is a major area of research for neurodegenerative diseases [PubMed Search].
• Disease Heterogeneity: These findings underscore the heterogeneity of microglial responses in different forms of Alzheimer's disease, suggesting that "one-size-fits-all" therapeutic approaches targeting microglia might not be optimal. Personalized medicine approaches considering the specific microglial phenotypes of individual patients or disease subtypes could be more effective.

7. Cell-Cell Interaction Analysis Across Alzheimer's Disease Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns in brain tissue derived from single-cell RNA sequencing data, comparing Control individuals with two Alzheimer's Disease (AD) conditions: E280A (a familial AD mutation) and Sporadic AD. CellPhoneDB was used to identify ligand-receptor interactions, and the results are visualized as dot plots, showcasing the top 80 interactions per condition based on significance and mean expression. The size of each dot represents the statistical significance (-log10(p-value)), and the color indicates the mean expression level (log2(mean)).

Visual Summary

The three dot plots display the most prominent cell-cell interactions for Control, E280A, and Sporadic conditions. Key visual features include:

• Diverse Interacting Cell Types: Interactions predominantly involve neurons, astrocytes, microglia, oligodendrocytes, and oligodendrocyte progenitor cells, reflecting the complex cellular ecosystem of the brain. Endothelial cells also show interactions, particularly related to vascular function.
• Prominent Ligand-Receptor Families: Several families of ligand-receptor pairs are frequently observed, including those involved in synaptic organization (Neurexins-Neuroligins, PTPRS-SLITRK/NGL, TENM-ADGRL), glutamate signaling, and lipid metabolism (APOE-LRP1).
• General Similarity in Core Interactions: All three conditions share a common set of strong interactions, particularly within neuronal populations (Neuron-Neuron) and between neurons and major glial cell types (Astrocyte-Neuron, Oligodendrocyte-Neuron, Microglia-Neuron).
• Condition-Specific Patterns and Strengths: While overall patterns are similar, distinct differences in the mean expression (color intensity) and significance (dot size) of specific interactions are observed when comparing disease conditions (E280A and Sporadic) to Control.

Biological Interpretation

Comparing the cell-cell interaction profiles across conditions reveals alterations in key biological processes that may underlie Alzheimer's disease pathology:

Altered Synaptic Adhesion and Plasticity:

• Interactions involving Neurexins (NRXN) and Neuroligins (NLG) (e.g., NRXN1-NLG1, NRXN3-NLG2), and PTPRS with SLITRKs/NGLs are highly prominent in all conditions, underscoring their critical roles in synapse formation and function.
• In both E280A and Sporadic AD, these synaptic adhesion molecules, particularly NRXN3-NLG1 and NRXN3-NLG2 in Neuron-Neuron, Astrocyte-Neuron, and Microglia-Neuron pairs, tend to show higher mean expression (indicated by greener/yellower dots) compared to the Control condition. This could suggest a compensatory upregulation in response to synaptic loss, dysregulation of synaptic pruning, or altered glial-neuronal communication in disease states.
• Similarly, some PTPRS-SLITRK/NGL interactions (e.g., PTPRS-SLITRK1/2/3/4/5/6, PTPRS-NGL1/2) in Neuron-Neuron interactions also appear strong in disease conditions. These pathways regulate synapse development and neuronal connectivity.

Dysregulation of Glutamatergic Signaling:

• Various Glutamate receptor interactions (e.g., involving GRM2, GRM3) are strong across all conditions, notably within Neuron-Neuron and between neurons and glial cells.
• In E280A and Sporadic AD, several of these glutamate signaling pairs, such as Glutamate_by_BGL_and_SLC1A1_GRM2 and Glutamate_by_SLC1A2_GRM3 in Neuron-Neuron interactions, exhibit increased mean expression. This suggests potential alterations in excitatory neurotransmission, which is a known factor in excitotoxicity and neuronal dysfunction in AD PubMed Search: "glutamate excitotoxicity Alzheimer's disease".

Impact on Lipid Metabolism and Amyloid Clearance:

• The interaction Cholesterol_by_APOE_LRP1 is detected across Astrocyte-Neuron, Microglia-Neuron, and Oligodendrocyte-Neuron cell pairs. Apolipoprotein E (APOE) is a major genetic risk factor for AD, and its interaction with LRP1 is crucial for lipid transport, Aβ clearance, and neuronal plasticity GeneCards: APOE, GeneCards: LRP1.
• Specifically, the Oligodendrocyte-Neuron interaction via Cholesterol_by_APOE_LRP1 appears to have higher mean expression in both E280A and Sporadic AD compared to Control. This finding could indicate alterations in myelin maintenance, lipid homeostasis, or Aβ processing involving oligodendrocytes in disease.

Glial-Neuronal and Glial-Glial Interactions:

• Microglia-Neuron, Astrocyte-Neuron, Oligodendrocyte-Neuron, and Oligodendrocyte progenitor cell-Neuron interactions are consistently observed across conditions, highlighting the critical supportive and regulatory roles of glial cells.
• The heightened expression of specific NRXN-NLG and Glutamate interactions involving Microglia and Astrocytes in AD conditions suggests altered neuroinflammatory responses and glial activation patterns, which are central to AD progression PubMed Search: "neuroinflammation Alzheimer's disease".

Clinical or Translational Implications

The observed differential cell-cell interactions offer significant insights into AD pathogenesis and present potential avenues for therapeutic intervention and biomarker discovery:

• Therapeutic Target Prioritization: Ligand-receptor pairs that show significantly altered interaction strengths or patterns in E280A and Sporadic AD, such as specific Neurexin-Neuroligin, PTPRS-SLITRK/NGL, and Glutamate receptor interactions, could be prioritized as potential therapeutic targets. Modulating these interactions might help restore synaptic function, normalize excitatory signaling, or dampen detrimental glial responses. For example, agents that selectively modulate specific NRXN-NLG isoforms or glutamate receptor subtypes could be explored.
• Understanding Disease Mechanisms: The increased Cholesterol_by_APOE_LRP1 interaction involving oligodendrocytes suggests a potential link between altered lipid metabolism, myelin integrity, and AD in these conditions. This highlights the importance of myelin health and APOE's role beyond Aβ clearance, possibly through its effects on oligodendrocyte function. Further research into this specific interaction could reveal new mechanisms of AD progression related to white matter pathology.
• Experimental Validation: These findings provide a strong foundation for further experimental validation. *In vitro* co-culture models of specific brain cell types, or *in vivo* studies using AD animal models, could be employed to functionally characterize the impact of these identified ligand-receptor interactions on neuronal viability, synaptic integrity, and glial activation in the context of AD. Specific genetic manipulations or pharmacological interventions targeting these pathways could then be tested for their therapeutic potential.

8. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates statistically significant cell-cell interactions (CCIs) across different conditions (Control, E280A, Sporadic Alzheimer's Disease) in brain tissue, focusing on Microglia, Astrocytes, Endothelial cells, and Fibroblasts, though interactions involving Neurons and Oligodendrocytes are also presented. The dot plot visualizes the standardized mean interaction strength (color intensity) and statistical significance (-log10(p) value, dot size) for selected ligand-receptor pairs between cell types, allowing for a comparative assessment of CCI patterns among individual samples within each condition. This helps identify CCIs that are uniquely enhanced or diminished in specific disease contexts, offering insights into altered intercellular communication in Alzheimer's disease.

Visual Summary

The dot plot displays a complex landscape of cell-cell interactions, with clear condition-specific patterns emerging:

• Control Condition (Top Block): Samples from control individuals exhibit a robust and highly significant pattern of interactions, particularly pronounced in the left portion of the plot. Key interactions involve various Neurexin (NRXN) and Neuroligin (NLGN) pairs (e.g., NRXN1_NLGN3--Astrocyte|Neuron), GABAergic signaling pathways (e.g., GABA_byGAD2_and_SLC6A11|GABBR1--Neuron|Astrocyte), and other adhesion molecules (e.g., THY1_ADGRE2--Neuron|Microglia). These interactions are characterized by dark red colors (high mean interaction) and large dot sizes (high significance), indicating strong, active communication.
• E280A Condition (Middle Block): In E280A samples (representing familial Alzheimer's disease), many of the CCIs prominent in controls show a marked reduction in both intensity and significance. However, a distinct set of interactions, primarily involving Collagen (COL) and Integrin complexes (e.g., COL4A1_integrin_a10b1_complex--Endo|Neuron, COL19A1_integrin_a10b1_complex--Endo|Neuron), appear to be upregulated. These interactions, frequently involving Endothelial cells and Neurons, show increased strength and significance compared to controls, suggesting a shift in intercellular communication dynamics.
• Sporadic Condition (Bottom Block): Sporadic Alzheimer's disease samples display patterns that share some similarities with E280A, particularly the reduction of "control-like" interactions and the upregulation of collagen-integrin signaling. A striking feature in sporadic AD is the high intensity and significance of many Collagen-Integrin CCIs (e.g., COL4A1, COL4A2, COL19A1, COL24A1, COL25A1, COL26A1, COL28A1) interacting with integrins on Endothelial cells and Neurons. These interactions are often even more pronounced than in E280A, forming a distinct cluster of highly active communication towards the right side of the plot. Additionally, some CNTN1_NOTCH1 interactions (Neuron|Endo, Neuron|Microglia) are also notably active in Sporadic AD.
• Overall Trend: There is a general trend of decreased synaptic-related and neuronal-glial interactions (e.g., GABAergic, Neurexin-Neuroligin) in both E280A and Sporadic AD compared to controls, coupled with a prominent increase in extracellular matrix (ECM)-related interactions, particularly those involving collagen and integrins, especially with endothelial cells.

Biological Interpretation

The observed condition-specific CCI patterns provide critical biological insights into Alzheimer's disease pathogenesis:

• Synaptic and Neuronal-Glial Dysfunction in AD: The significant reduction of GABAergic signaling (GABA_byGAD2_and_SLC6A11/GABBR1) and Neurexin-Neuroligin (NRXN-NLGN) interactions in both E280A and Sporadic AD is highly consistent with well-documented synaptic dysfunction and loss in Alzheimer's disease. GABAergic interneurons play a crucial role in maintaining neural circuit balance, and their disruption contributes to hyperexcitability and cognitive decline in AD PubMed search: GABAergic dysfunction Alzheimer's disease. Neurexins and Neuroligins are fundamental synaptic adhesion molecules that regulate synapse formation, maturation, and function; their downregulation points towards impaired synaptic integrity PubMed search: Neurexin Neuroligin Alzheimer's disease.
• Neurovascular Unit (NVU) Remodeling and ECM Dysregulation in AD: The striking upregulation of numerous Collagen (COLx)-Integrin interactions, particularly involving Endothelial cells and Neurons, Astrocytes, or Oligodendrocytes, in both E280A and Sporadic AD indicates profound changes in the extracellular matrix (ECM) and neurovascular unit (NVU) integrity.
• Integrins are transmembrane receptors crucial for cell adhesion, migration, and signaling by binding to ECM components like collagen. Their heightened activity suggests a reactive state in endothelial cells, potentially indicating blood-brain barrier (BBB) breakdown, altered vascular permeability, or abnormal angiogenesis PubMed search: integrin Alzheimer's disease brain.
• Collagen IV (COL4A1, COL4A2) is a primary component of the vascular basement membrane. Its increased interaction with integrins implies significant remodeling of the basement membrane, which could compromise BBB function and contribute to cerebral amyloid angiopathy (CAA) and vascular pathology common in AD PubMed search: Collagen IV blood brain barrier Alzheimer's disease.
• The involvement of multiple collagen types (e.g., COL19A1, COL24A1, COL25A1) and various integrin complexes underscores a broad, dysregulated ECM response in AD brain tissue.
• Microglial and Glial Reactivity: While direct microglial interactions were less broadly highlighted than endothelial-neuron ECM interactions, the changes in interactions like THY1_ADGRE2 (Neuron-Microglia) and CNTN1_NOTCH1 (Neuron-Microglia, Neuron-Endo) point to altered immune and inflammatory signaling. Notch signaling is a critical pathway in neurodevelopment and disease, regulating cell fate, proliferation, and inflammatory responses in microglia and other glial cells PubMed search: Notch signaling Alzheimer's disease.
• Differences between Familial (E280A) and Sporadic AD: While both AD conditions show a general shift from synaptic-supportive CCIs to ECM remodeling, the visually more intense and broader spectrum of Collagen-Integrin interactions in Sporadic AD suggests potentially more severe or widespread NVU and ECM dysregulation, aligning with the late-onset, complex etiology of sporadic AD.

Clinical or Translational Implications

These findings hold significant clinical and translational potential:

• Biomarker Discovery: The distinct CCI profiles, particularly the profound loss of GABAergic/synaptic interactions and the robust increase in specific Collagen-Integrin CCIs, could serve as novel diagnostic or prognostic biomarkers for Alzheimer's disease. These patterns might differentiate AD stages, distinguish between familial and sporadic forms, or monitor disease progression.

Therapeutic Targets:

• Synaptic Restoration: Strategies aimed at restoring or enhancing GABAergic neurotransmission or bolstering synaptic adhesion molecules like Neurexin-Neuroligin could be investigated as disease-modifying therapies, particularly in early stages of AD to mitigate synaptic loss and cognitive decline.
• Neurovascular Modulation: Targeting specific integrin subtypes or their collagen ligands involved in pathological ECM remodeling offers a promising avenue to address NVU dysfunction, stabilize the BBB, and reduce neuroinflammation in AD. Modulating these interactions could prevent or reverse the deleterious effects of ECM changes on neuronal survival and function.
• Glial Immunomodulation: Pathways like CNTN1-NOTCH1 represent potential targets for modulating glial (including microglial) activation states, shifting them from neurotoxic to neuroprotective phenotypes, which is a key strategy in neurodegenerative disease research.
• Understanding Pathogenesis: The analysis highlights distinct but also shared CCI dysregulations between familial and sporadic AD, suggesting common underlying pathological processes, but also potential nuances that might warrant personalized therapeutic strategies. Further investigation into the functional consequences of these altered CCIs could uncover critical disease mechanisms.

9. Condition-Specific Surfaceome Markers in Microglia

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes condition-specific surfaceome markers in Microglia cells across different disease states: Control, E280A (a familial form of Alzheimer's Disease), and Sporadic (sporadic Alzheimer's Disease). The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each gene (dot size) for individual samples grouped by condition. Focusing exclusively on surfaceome markers enhances their utility for potential diagnostic, therapeutic, or cell isolation applications.

Visual Summary

The dot plot clearly delineates three distinct sets of surfaceome markers, each predominantly expressed in one of the three conditions:

• Control Microglia Markers: A cluster of markers including *CX3CR1*, *MRC1*, *LINGO1*, *PMEPA1*, *MILR1*, *EPHB2*, *SLC29A3*, *SUSD3*, *SLC26A3*, and *LYVE1* shows high expression and prevalence specifically in the Control samples. These genes are largely absent or expressed at negligible levels in E280A and Sporadic samples. This pattern suggests a unique molecular signature for homeostatic or non-diseased microglia.
• E280A Microglia Markers: A distinct set of genes, namely *DSCAM*, *OLR1*, *OPRM1*, and *PLP1*, are notably upregulated in microglia from E280A samples. While *LINGO1* also appears in this cluster, its expression profile is different from the Control group, suggesting a condition-dependent role or distinct microglial state. These markers highlight specific alterations in microglial surface protein expression in the context of familial Alzheimer's disease.
• Sporadic Microglia Markers: Microglia from Sporadic Alzheimer's samples exhibit a characteristic expression profile for *CD163*, *ADGRE2*, *TNFSF13B*, *PLXNC1*, *PLB1*, *PTPRG*, and *ESR1*. These markers show high expression and cell fraction exclusively in the Sporadic group, indicating a unique inflammatory or disease-associated phenotype specific to sporadic AD.

Overall, the plot demonstrates remarkable heterogeneity in microglial surfaceome composition depending on the disease condition, with minimal overlap between the marker sets of the three groups.

Biological Interpretation

The identified condition-specific surfaceome markers suggest distinct functional states of microglia in Control, E280A, and Sporadic conditions, reflecting their roles in health and disease progression within the brain.

Control Microglia: Homeostasis and Basal Function

• CX3CR1: A well-established receptor for the chemokine CX3CL1 (fractalkine), critical for maintaining microglial ramified morphology and homeostatic functions in the healthy brain, including synaptic pruning and neuronal support. PubMed search: CX3CR1 microglia homeostasis
• MRC1 (CD206): Mannose receptor, involved in phagocytosis and typically associated with an M2-like, anti-inflammatory or reparative microglial phenotype. GeneCards: MRC1
• The presence of these markers in Control microglia suggests a quiescent or homeostatic state, with functions geared towards immune surveillance and tissue maintenance.

E280A Microglia: Familial AD-Specific Alterations

• DSCAM (Down Syndrome Cell Adhesion Molecule): Involved in neural development and potentially immune responses. Its altered expression could reflect dysregulated developmental or synaptic plasticity processes in E280A AD. GeneCards: DSCAM
• OLR1 (LOX-1): Oxidized low-density lipoprotein receptor 1, implicated in inflammation and lipid metabolism. Its upregulation might point to microglial responses to altered lipid processing or oxidative stress, commonly observed in neurodegenerative diseases. GeneCards: OLR1
• OPRM1 (Mu-opioid receptor): While primarily known for pain perception, opioid receptors on immune cells, including microglia, can modulate inflammatory responses. Its expression could indicate microglial involvement in neuroinflammation or pain pathways in E280A AD. GeneCards: OPRM1
• PLP1 (Proteolipid Protein 1): A major myelin component. Its presence in microglia might suggest active phagocytosis of myelin debris, indicating demyelination or myelin damage in E280A AD. GeneCards: PLP1
• These markers collectively hint at microglial engagement in handling cellular debris, oxidative stress, and potentially unique inflammatory processes in familial AD.
• Sporadic Microglia: Disease-Associated and Inflammatory Phenotypes
• CD163: A scavenger receptor expressed by M2-like macrophages/microglia, involved in clearing hemoglobin-haptoglobin complexes and associated with an anti-inflammatory or tissue-remodeling phenotype. Its upregulation could indicate a response to hemorrhage or widespread cellular damage. GeneCards: CD163
• ADGRE2 (GPR84): An orphan G protein-coupled receptor primarily expressed on myeloid cells, known to be upregulated during inflammation and to promote inflammatory responses. GeneCards: ADGRE2
• TNFSF13B (BAFF): B-cell activating factor, crucial for B cell survival and maturation. Its expression in microglia might suggest cross-talk with peripheral immune cells or specific neuroinflammatory pathways involving B cells in sporadic AD. GeneCards: TNFSF13B
• ESR1 (Estrogen Receptor Alpha): Estrogen signaling influences microglial activation states and neuroprotection. Its presence suggests a potential modulation of microglial responses by hormonal factors in sporadic AD, which is relevant given sex differences in AD prevalence. GeneCards: ESR1
• This panel of markers strongly points towards an activated, possibly disease-associated microglial phenotype (DAM-like or M2-like, with inflammatory components), uniquely involved in the pathogenesis of sporadic AD, possibly engaging in distinct debris clearance and immune regulatory pathways.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers in microglia carries significant clinical and translational potential:

• Diagnostic Biomarkers: These distinct surface marker panels could serve as novel diagnostic or prognostic biomarkers to differentiate between healthy individuals, familial AD (E280A), and sporadic AD. This is particularly valuable given the heterogeneity of Alzheimer's disease and the need for improved stratification.
• Therapeutic Targets: As these are surface proteins, they are highly accessible for antibody-based therapies or other drug modalities. Targeting specific markers (e.g., those on activated microglia in AD conditions) could enable precise modulation of microglial function, potentially reducing neuroinflammation or enhancing beneficial microglial activities without affecting homeostatic microglia.
• Cell Isolation and Characterization: These markers can be used for *ex vivo* isolation of specific microglial subpopulations from brain tissue (e.g., via FACS) for further functional studies, drug screening, or *in vitro* disease modeling. This would facilitate a deeper understanding of microglial heterogeneity and their roles in different AD contexts.
• Imaging Probes: Specific antibodies or ligands against these surface markers could be developed into PET tracers or other imaging agents to non-invasively detect and monitor specific microglial states *in vivo*, offering a powerful tool for disease progression tracking and treatment response assessment.

10. Cell-Type Specific Surfaceome Markers in Human Brain

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify cell-type-specific surfaceome markers across various cell subsets in the human brain, with a particular focus on Fibroblasts, using single-cell RNA sequencing data. The plot_markers_and_expression_dot tool was employed to visualize gene expression patterns, specifically emphasizing surface-expressed genes. While the user query requested "condition-specific markers for Fibroblasts," the generated dot plot displays general cell-type-specific markers across all identified cell subsets, irrespective of condition. The plot highlights genes that are highly expressed and selectively enriched in each cell type, focusing on surfaceome genes as per the applied parameters.

Visual Summary

The provided dot plot effectively visualizes the expression of a curated set of surfaceome marker genes across different celltype_subset categories. Each row represents a cell type, and each column represents a gene.

• Dot Size: The size of each dot indicates the fraction of cells within that cell type expressing the particular gene (percentage of cells in group). Larger dots mean a higher proportion of cells express the gene.
• Dot Color Intensity: The color intensity of each dot (ranging from light red to dark red) represents the mean expression level of the gene within that cell type. Darker red indicates higher mean expression.
• Cell Type Specificity: Genes with large, dark red dots predominantly in a single row are strong candidates for cell-type-specific markers. Red boxes are drawn around clusters of genes identified as highly specific markers for the corresponding cell type, aiding in quick identification.
• Focus on Fibroblasts: For Fibroblasts, a distinct set of markers is highlighted with large, dark red dots within their respective box, demonstrating high expression and prevalence in this cell type.
• Overall Marker Quality: The plot clearly shows distinct marker sets for various cell types like Astrocytes (e.g., GFAP), Microglia (e.g., PTPRC, AIF1), Neurons (e.g., SYT1, GAD1), and Oligodendrocytes (e.g., MBP, MAG), indicating effective identification of specific markers across the dataset.

Biological Interpretation

The analysis successfully identified a panel of surfaceome markers distinguishing Fibroblasts from other cell types in the human brain. Focusing on the 'Fibroblast' row and its associated marker cluster:

• Key Fibroblast Surfaceome Markers: The plot highlights genes such as DCN (Decorin), COL1A2 (Collagen Type I Alpha 2 Chain), FBLN1 (Fibulin 1), COL6A2 (Collagen Type VI Alpha 2 Chain), and A2M (Alpha-2-Macroglobulin) as prominent surfaceome markers for Fibroblasts. While some of these genes (e.g., collagens) are primarily secreted or matrix-associated, their identification here suggests they are robustly produced by fibroblasts, potentially interacting with cell surface receptors or detectable via surface-proximal assays.
• DCN (Decorin): A small leucine-rich proteoglycan found in the extracellular matrix (ECM) of connective tissues. It plays a role in collagen fibrillogenesis, binds to various growth factors, and can interact with cell surface receptors, influencing cell proliferation and migration GeneCards: DCN.
• COL1A2 and COL6A2: These are components of different types of collagen, major structural proteins of the ECM. Fibroblasts are primary producers of collagen, essential for tissue integrity and repair GeneCards: COL1A2, GeneCards: COL6A2.
• FBLN1 (Fibulin 1): An extracellular matrix protein involved in cell adhesion and tissue development. It interacts with other ECM components and cell surface receptors, contributing to matrix assembly and cell signaling GeneCards: FBLN1.
• A2M (Alpha-2-Macroglobulin): A large plasma protein that can bind to a wide variety of proteins, including proteases, growth factors, and cytokines. While often secreted, it can interact with cell surface receptors (e.g., LRP1), influencing cellular processes. It's known to be produced by fibroblasts and may play roles in inflammation and tissue remodeling GeneCards: A2M.
• Functional Relevance: The identified genes strongly align with the known functions of fibroblasts, which are critical for maintaining tissue structure, producing the extracellular matrix, and participating in wound healing and fibrosis. These markers underscore the structural and regulatory roles of fibroblasts in the brain microenvironment.
• Other Cell Types: The plot also validates known surface markers for other brain cell types, demonstrating the robustness of the marker identification pipeline (e.g., GFAP for Astrocytes, PTPRC (CD45) for Microglia, SYT1 and GAD1 for Neurons, MBP and MAG for Oligodendrocytes).

Clinical or Translational Implications

The identification of specific surfaceome markers for Fibroblasts in the brain has several important clinical and translational implications:

• Cell Isolation and Purification: These surfaceome markers (DCN, COL1A2, FBLN1, COL6A2, A2M) provide targets for isolating pure populations of fibroblasts from complex brain tissue using techniques like Fluorescence-Activated Cell Sorting (FACS) or magnetic bead separation. This is crucial for *in vitro* studies, cell transplantation therapies, or understanding their specific roles in disease.
• Disease Monitoring and Diagnostics: Changes in the expression of these fibroblast-specific surface markers could serve as biomarkers for various neurological conditions involving fibrosis, inflammation, or ECM remodeling. For example, in neurodegenerative diseases or following brain injury, activated fibroblasts (often referred to as reactive astrocytes or scar-forming cells depending on context, though fibroblasts are distinct) contribute to pathological processes, and their specific markers could aid in disease staging or monitoring treatment responses.
• Therapeutic Targeting: Since these are surfaceome markers, they represent potential targets for drug delivery or cell-specific interventions. For instance, in conditions where brain fibrosis is detrimental, antibodies or cell-targeting therapies directed against fibroblast-specific surface receptors could be developed to modulate fibroblast activity or selectively deplete pathological fibroblast populations.
• Understanding Brain Pathology: By enabling better characterization and isolation of brain fibroblasts, these markers can facilitate research into their specific contributions to neuroinflammation, neurodegeneration (e.g., in Alzheimer's disease, as indicated by 'E280A', 'Sporadic' conditions in the data context), and repair mechanisms after injury or stroke.
• Limitations and Future Directions: While this plot effectively identifies general fibroblast-specific markers, the initial query for "condition-specific" markers remains relevant. Future analyses could leverage these identified surface markers in conjunction with condition-specific differential gene expression analyses (e.g., from uns['DEG']) to uncover how fibroblast surfaceome changes in diseases like E280A Alzheimer's or Sporadic AD, potentially revealing novel targets for condition-specific therapies.

11. Gene Ontology (GSA) Analysis of Upregulated Pathways in Neurons and Microglia in Alzheimer's Disease Context

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates Gene Ontology (GO) biological processes and disease pathways that are significantly upregulated in Neurons and Microglia across different conditions: Control, E280A (a familial Alzheimer's disease mutation), and Sporadic (sporadic Alzheimer's disease). The results are derived from a Gene Set Analysis (GSA) comparing each condition against all other conditions within each cell type (GSA_up results). This approach helps to identify cell-type-specific molecular alterations associated with different AD states.

Visual Summary

The provided dot plot visualizes the Gene Ontology (GSA) enrichment results for Neurons and Microglia. The y-axis lists various GO terms, representing biological processes or disease pathways. The x-axis represents the specific comparisons made: "Neuron: Control vs others", "Neuron: E280A vs others", "Neuron: Sporadic vs others", "Microglia: Control vs others", "Microglia: E280A vs others", and "Microglia: Sporadic vs others". Each dot's size and color intensity reflect the statistical significance (p-value) of the enrichment, with larger and darker red dots indicating a higher -log10(P) value, hence greater statistical significance. The plot focuses on pathways where associated genes are *upregulated* in the target condition compared to the 'others' group (the remaining conditions).

Key visual patterns observed:

• Prominent Neurodegenerative Pathways: Several neurodegenerative disease pathways, including "Alzheimer disease", "Amyotrophic lateral sclerosis", "Huntington disease", "Parkinson disease", "Prion disease", and "Pathways of neurodegeneration", show highly significant enrichment (large, dark red dots) across both Neuron and Microglia cell types, particularly in the E280A and Sporadic conditions.
• Cellular Stress and Dysfunction: Pathways like "Autophagy", "Oxidative phosphorylation", and "Protein processing in endoplasmic reticulum" are also frequently and significantly enriched, especially in disease conditions.
• Immune/Phagocytic Activation in Microglia: In Microglia, especially in the E280A and Sporadic conditions, strong enrichment is observed for immune-related terms such as "Fc gamma R-mediated phagocytosis" and "Phagosome", along with several infection-related pathways.
• Neuronal Specificity: "Dopaminergic synapse" and "Synaptic vesicle cycle" show notable enrichment in Neurons across conditions.
• "Control vs others" patterns: Interestingly, in Neurons, "Control vs others" also shows significant enrichment for many neurodegenerative pathways, albeit sometimes with slightly lower significance compared to the E280A and Sporadic comparisons for those same pathways.

Biological Interpretation

The GSA results reveal distinct yet overlapping biological processes that are upregulated in Neurons and Microglia in the context of Alzheimer's disease.

General Observations Across Cell Types and Conditions:

• Neurodegenerative Signature: The consistent upregulation of gene sets related to "Alzheimer disease", "Amyotrophic lateral sclerosis", "Huntington disease", "Parkinson disease", "Prion disease", and general "Pathways of neurodegeneration" in both Neurons and Microglia from E280A and Sporadic AD brains highlights a shared, complex pathological landscape. This indicates that a core set of genes associated with these diseases are actively modulated (upregulated) in both principal neuronal cells and crucial immune cells of the brain during AD pathology. This suggests that the molecular mechanisms driving these neurodegenerative conditions might converge on common cellular pathways. PubMed search: Neurodegenerative disease common pathways

Neuron-Specific Insights:

• Disease-associated Upregulation: In E280A and Sporadic Neurons, the significant upregulation of neurodegenerative pathways directly reflects the genetic and pathological hallmarks of Alzheimer's disease and other proteinopathies. This suggests an active pathological response within neurons.
• Cellular Stress and Metabolic Dysfunction: "Oxidative phosphorylation", "Autophagy", and "Protein processing in endoplasmic reticulum" are consistently upregulated in disease-affected neurons. This points to mitochondrial dysfunction, impaired protein homeostasis, and increased cellular stress, which are well-established features of neurodegenerative diseases. GeneCards: APP (Alzheimer's disease amyloid precursor protein)
• Synaptic Dynamics: The enrichment of "Dopaminergic synapse" and "Synaptic vesicle cycle" in neurons, even in disease conditions, could reflect either compensatory mechanisms attempting to maintain synaptic function or specific pathological alterations in neurotransmission.
• "Control vs others" Interpretation: The observation that "Control vs others" also shows significant enrichment for neurodegenerative pathways in neurons is intriguing. This could imply that healthy control neurons maintain a baseline expression of genes within these pathways, potentially representing a protective or homeostatic program that is either dysregulated, overwhelmed, or even actively reduced in the disease states, leading to a relative "upregulation" in the control group. Alternatively, the "others" group (E280A + Sporadic) might experience a *downregulation* of certain genes within these pathways compared to controls.

Microglia-Specific Insights:

• Neuroinflammatory Activation: The robust upregulation of "Fc gamma R-mediated phagocytosis", "Phagosome", and multiple infection-related pathways (e.g., "Salmonella infection", "Yersinia infection", "Tuberculosis") in E280A and Sporadic Microglia is a strong indicator of microglial activation and an inflammatory response. Microglia, as the brain's resident immune cells, undergo phenotypic changes in AD, often adopting a reactive state involving increased phagocytic activity to clear amyloid plaques and cellular debris. PubMed search: Microglial phagocytosis Alzheimer's disease
• Shared Pathological Mechanisms: Similar to neurons, Microglia in disease conditions also show upregulation of general neurodegenerative disease pathways, indicating their direct involvement in the progression of these diseases beyond just an immune response.
• Cellular Maintenance: Upregulation of "Oxidative phosphorylation", "Autophagy", and "MAPK signaling pathway" in activated microglia suggests increased metabolic demand and complex intracellular signaling networks governing their reactive state.
• Synaptic Interaction: The presence of "Synaptic vesicle cycle" enrichment in microglia is notable and could reflect their active role in synaptic pruning or interactions with synaptic elements, which are known to be altered in neurodegenerative conditions.

Clinical or Translational Implications

The findings from this GSA analysis provide valuable insights into the molecular pathology of Alzheimer's disease, particularly highlighting the distinct and cooperative roles of Neurons and Microglia.

1. Multi-pathway Targeting: The consistent upregulation of various neurodegenerative disease pathways across different AD conditions and cell types suggests that AD pathology is driven by a complex interplay of molecular events. Therapeutic strategies might need to target not just a single pathway (e.g., amyloid-beta), but rather a network of interconnected pathological processes, including protein misfolding, mitochondrial dysfunction, and impaired waste clearance.
2. Cell-Type-Specific Interventions: The clear differences in enriched pathways between Neurons (e.g., more direct synaptic impact) and Microglia (e.g., strong immune/phagocytic activation) underscore the importance of cell-type-specific therapeutic approaches. For instance, modulating microglial phagocytic activity could be a promising avenue to enhance clearance of pathological protein aggregates.
3. Biomarker Discovery: The identified upregulated pathways and their constituent genes could serve as potential biomarkers for disease progression or therapeutic response. Monitoring the activity of specific pathways in patient samples might help assess disease status or the effectiveness of treatments.
4. Understanding Familial vs. Sporadic AD: The largely similar patterns of pathway upregulation in E280A (familial AD) and Sporadic AD suggest shared fundamental pathological mechanisms, implying that insights gained from studying familial forms can be highly relevant to the more common sporadic forms of the disease.

12. Gene Set Enrichment Analysis Reveals Cell-Type-Specific Pathway Dysregulation in Brain Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. It compares pathway enrichment across four major brain cell types: Neurons, Oligodendrocytes, Astrocytes, and Microglia. For each cell type, gene expression from three conditions (Control, E280A, and Sporadic) is compared against the pooled gene expression from the other two conditions within that same cell type. The E280A condition likely represents a familial form of a neurodegenerative disease (e.g., Alzheimer's Disease due to PSEN1 E280A mutation), while Sporadic represents a non-familial form, and Control serves as a healthy reference.

Visual Summary

The dot plot effectively summarizes the GSEA results:

• Dot Size: Represents the statistical significance, specifically the negative logarithm of the p-value (-log(P)). Larger dots indicate higher statistical significance (smaller p-values) for the enrichment of that pathway.
• Dot Color: Reflects the Normalized Enrichment Score (NES). Red dots indicate positive enrichment, meaning the pathway genes are generally upregulated in the target condition compared to the 'others'. Blue dots indicate negative enrichment, meaning the pathway genes are generally downregulated in the target condition compared to the 'others' (or enriched in the 'others' relative to the target).
• Structure: Pathways are listed on the y-axis, and the x-axis displays the specific comparisons (e.g., "Neuron: Control_vs_others").
• Key Observations: The plot reveals a complex landscape of pathway alterations, with many pathways showing significant differential enrichment across cell types and conditions. There are clear patterns of both positive (red) and negative (blue) enrichment, often with high significance (large dot size), indicating substantial biological shifts.

Biological Interpretation

The GSEA results highlight profound and cell-type-specific molecular changes associated with the E280A and Sporadic conditions in the brain, compared to the healthy Control state.

Neuron-Specific Dysregulations

• Synaptic and Neuronal Function Decline: The Neuroactive ligand-receptor interaction pathway is significantly negatively enriched (blue, large dots) in Neurons from both E280A and Sporadic conditions (Neuron: E280A_vs_others, Neuron: Sporadic_vs_others). Conversely, it is positively enriched in Control neurons. This suggests a profound disruption and downregulation of critical neuronal communication and signaling pathways in diseased neurons, a hallmark of neurodegeneration leading to cognitive impairment. PubMed search: Neuroactive ligand-receptor interaction Alzheimer's disease
• Altered Synaptic Plasticity and Calcium Homeostasis: Long-term depression and Calcium signaling pathway are positively enriched (red, large dots) in Neurons from both E280A and Sporadic conditions. Dysregulation of calcium homeostasis is a well-established factor in neurodegenerative diseases, contributing to excitotoxicity, synaptic dysfunction, and neuronal death. Increased long-term depression might indicate impaired synaptic plasticity or a compensatory maladaptive response. GeneCards: PSEN1, PubMed search: calcium dysregulation neurodegeneration
• Increased Cellular Stress and Death: Pathways such as Mitophagy and Necroptosis show positive enrichment in E280A and Sporadic neurons, indicating heightened mitochondrial quality control (mitophagy) and activation of programmed cell death (necroptosis) mechanisms, reflecting severe cellular stress and impending cell loss.

Oligodendrocyte Dysfunction

• Impaired Myelination: Fatty acid elongation is significantly negatively enriched (blue, large dots) in Oligodendrocytes from both E280A and Sporadic conditions. This pathway is crucial for lipid synthesis, a key component of myelin. Its downregulation suggests impaired myelination or demyelination processes in disease, affecting white matter integrity and neuronal signal transmission.
• Metabolic Stress: Peroxisome is positively enriched in Oligodendrocytes from the E280A condition, suggesting altered lipid metabolism and oxidative stress responses, which are vital functions of peroxisomes.

Astrocyte Reactivity and Immune Modulation

• Altered Cell Adhesion and ECM Interaction: Pathways like Adherens junction, Focal adhesion, and ECM-receptor interaction show variable, but often enriched patterns in Astrocytes from disease conditions. This is consistent with reactive astrogliosis, where astrocytes undergo morphological and functional changes, including altered cell adhesion and interaction with the extracellular matrix, to form glial scars.
• Immune Modulatory Role: PD-L1 expression and PD-1 checkpoint pathway in cancer is positively enriched (red, large dots) in Astrocytes from the Sporadic condition (Astrocyte: Sporadic_vs_others). This suggests astrocytes may engage in immune checkpoint mechanisms, potentially modulating local inflammation or contributing to immune evasion in chronic neuroinflammation. PubMed search: astrocyte PD-L1 neuroinflammation

Microglial Activation and Inflammation

• Pro-inflammatory and Immune Response: Antigen processing and presentation and a range of Infection-related pathways (e.g., Staphylococcus aureus infection, Bacterial invasion of epithelial cells, Viral myocarditis) are highly and significantly positively enriched (red, large dots) in Microglia from both E280A and Sporadic conditions. This provides strong evidence for robust microglial activation and a pronounced innate immune and inflammatory response in diseased brains, a key driver of neurodegeneration.
• Immune Checkpoint Engagement: PD-L1 expression and PD-1 checkpoint pathway in cancer is also strongly positively enriched in Microglia from both E280A and Sporadic conditions. This indicates that microglia, in their activated state, are employing immune checkpoint molecules, which could play a role in regulating the intensity and duration of neuroinflammation. PubMed search: microglia PD-L1 neuroinflammation
• Mitochondrial Quality Control: Mitophagy is positively enriched in Microglia from the Sporadic condition, pointing to altered mitochondrial dynamics and metabolic reprogramming in microglia, which can influence their inflammatory phenotype.

Condition-Specific Commonalities and Differences

Both E280A and Sporadic conditions show shared patterns of pathway dysregulation across cell types, suggesting common underlying pathological mechanisms (e.g., neuronal synaptic dysfunction, microglial activation). However, some distinctions exist, such as the stronger enrichment of PD-L1 expression and PD-1 checkpoint pathway in Sporadic astrocytes compared to E280A microglia. These differences might reflect distinct genetic predispositions, disease progression rates, or specific inflammatory cascades.

Clinical or Translational Implications

The findings underscore the multi-cellular and multi-pathway nature of neurodegenerative diseases.

• Therapeutic Targets for Neuronal Health: The consistent downregulation of Neuroactive ligand-receptor interaction and upregulation of Calcium signaling pathway in diseased neurons suggest that interventions aimed at restoring synaptic function, modulating calcium homeostasis, or preventing neuronal cell death (e.g., targeting necroptosis) could be neuroprotective.
• Modulating Neuroinflammation: The prominent activation of immune and inflammatory pathways in microglia (e.g., Antigen processing and presentation, PD-L1 expression) in both disease conditions points to neuroinflammation as a critical therapeutic target. Strategies to reprogram microglial states from pro-inflammatory to neuroprotective, or to modulate immune checkpoints, could be beneficial.
• Addressing White Matter Pathology: The downregulation of Fatty acid elongation in oligodendrocytes highlights impaired myelination as a key component of the disease pathology. Therapeutics aimed at supporting oligodendrocyte survival, function, and remyelination could help preserve white matter integrity and improve connectivity.
• Differential Disease Mechanisms: The subtle differences in pathway enrichment between E280A and Sporadic conditions, such as the specific cell types engaging PD-L1 checkpoint pathways, suggest that while core pathologies overlap, there might be unique molecular drivers or responses that warrant condition-specific therapeutic considerations.

13. Discussion

The comprehensive single-cell analysis of human brain tissue elucidates the complex cellular and molecular landscape in both familial (E280A) and sporadic Alzheimer's Disease (AD), revealing both shared and distinct pathogenic features compared to control brains.

Our cellular population analysis revealed a notable shift in microglial populations. Specifically, in Sporadic AD samples, there was a significant reduction in homeostatic Microglia (M0) and a significant increase in M2b microglia compared to controls. E280A AD also showed a decrease in M0 microglia relative to controls. This suggests a deviation from a quiescent state towards activated phenotypes, potentially reflecting differential inflammatory or immune-regulatory responses specific to AD subtypes. The consistently low proportion of M1 (pro-inflammatory) microglia across all conditions is a noteworthy finding, implying that chronic neuroinflammation in these AD samples might be driven by alternative microglial states or pathways, or that classical M1 markers may not fully capture the inflammatory spectrum.

Cell-cell interaction (CCI) analyses underscored a profound dysregulation in intercellular communication. A striking observation was the significant reduction of synaptic-related interactions, such as those involving Neurexin-Neuroligin and GABAergic signaling, in both E280A and Sporadic AD brains compared to controls. This aligns with the well-established synaptic loss and dysfunction characteristic of AD. Concomitantly, a prominent increase in extracellular matrix (ECM)-related interactions, particularly those involving Collagen (e.g., COL4A1, COL19A1) and Integrins, was observed, predominantly between Endothelial cells and Neurons, Astrocytes, or Oligodendrocytes. These changes were often more pronounced in Sporadic AD, suggesting extensive neurovascular unit (NVU) remodeling and potential blood-brain barrier (BBB) compromise. The increased Cholesterol_by_APOE_LRP1 interaction involving oligodendrocytes further highlights altered lipid metabolism and myelin integrity in disease.

Pathway enrichment analyses (GSA and GSEA) provided molecular insights into these cellular changes. Neurons in AD conditions displayed a significant downregulation of 'Neuroactive ligand-receptor interaction' and upregulation of 'Calcium signaling pathway,' 'Mitophagy,' and 'Necroptosis,' pointing to synaptic decline, excitotoxicity, and programmed cell death. Microglia in AD showed strong positive enrichment for 'Fc gamma R-mediated phagocytosis,' 'Antigen processing and presentation,' and various infection-related pathways, alongside 'PD-L1 expression,' indicating robust activation and an attempt to clear pathological aggregates, coupled with immune checkpoint engagement. Oligodendrocytes demonstrated a negative enrichment of 'Fatty acid elongation,' suggesting impaired myelination. Astrocytes exhibited altered cell adhesion and ECM interaction, consistent with reactive astrogliosis, and also showed 'PD-L1 expression' enrichment in Sporadic AD. Collectively, these findings paint a picture of multi-factorial pathology encompassing synaptic failure, neuroinflammation, demyelination, and cerebrovascular dysfunction in AD brains. The subtle differences between E280A and Sporadic AD, such as the distinct microglial surfaceome markers and varying intensities of ECM remodeling, underscore the heterogeneity of AD pathogenesis and highlight the importance of distinguishing these subtypes.

Hypotheses:

1. Differential microglial polarization, characterized by reduced M0 and increased M2b populations in Sporadic Alzheimer's Disease, drives distinct neuroinflammatory and phagocytic responses compared to familial AD and control states.
2. Dysregulated extracellular matrix-integrin interactions, particularly involving endothelial cells, contribute significantly to blood-brain barrier dysfunction and neurovascular unit pathology in Alzheimer's Disease.
3. The downregulation of neuroactive ligand-receptor interactions in neurons directly correlates with synaptic loss and contributes to cognitive decline observed in both familial and sporadic Alzheimer's Disease.
4. Impaired fatty acid elongation in oligodendrocytes leads to demyelination and white matter pathology, contributing to neuronal communication deficits in Alzheimer's Disease.
5. The upregulation of immune checkpoint molecules like PD-L1 in reactive astrocytes and microglia in AD brains represents a maladaptive immune response that hinders effective clearance of pathological proteins or resolution of inflammation.

Potential therapeutic targets:

1. Integrin α10β1 complex and other Collagen-binding Integrins: These integrin complexes are significantly upregulated, particularly in Endothelial-Neuron interactions, in both E280A and Sporadic AD. This suggests a pathological remodeling of the extracellular matrix and neurovascular unit, potentially contributing to blood-brain barrier dysfunction and neuroinflammation. Evidence: CCI analysis (Section 8) showed a striking upregulation of numerous Collagen-Integrin CCIs (e.g., COL4A1, COL19A1 interacting with integrins) with high significance and intensity in AD conditions, especially Sporadic AD. Validation: Test specific integrin antagonists or modulating antibodies in AD animal models to assess their impact on restoring blood-brain barrier integrity, reducing glial activation, and improving cognitive outcomes. *In vitro* assays with human brain endothelial cells and neurons could confirm effects on adhesion, permeability, and inflammation.
2. Specific Microglial Activation Markers (e.g., ADGRE2, CD163, OLR1): Microglia undergo significant polarization shifts in AD, adopting distinct phenotypes with unique surface markers and enriched inflammatory/phagocytic pathways. Modulating these specific markers could re-balance microglial functions towards a neuroprotective state. Evidence: Microglial subset population analysis (Section 5, 6) showed reduced M0 and increased M2b in Sporadic AD. Surfaceome marker analysis (Section 9) identified ADGRE2 and CD163 as highly expressed in Sporadic microglia, and OLR1 in E280A microglia. GSEA (Section 12) showed enrichment of 'Antigen processing and presentation' and 'PD-L1 expression' in AD microglia. Validation: Develop and test antibody-based therapies or small molecule inhibitors/agonists targeting ADGRE2, CD163, or OLR1. Evaluate their efficacy in AD animal models or human iPSC-derived microglia cultures to modulate microglial polarization, enhance amyloid-beta clearance, reduce pro-inflammatory cytokine release, and improve neuronal survival.
3. Neuroactive ligand-receptor interactions / Calcium signaling pathway in Neurons: Neuronal dysfunction is a hallmark of AD. The significant downregulation of neuroactive ligand-receptor interactions and upregulation of calcium signaling pathways in diseased neurons directly contribute to synaptic failure and excitotoxicity, driving neurodegeneration. Evidence: GSEA results (Section 12) consistently showed significant negative enrichment of 'Neuroactive ligand-receptor interaction' and positive enrichment of 'Calcium signaling pathway' in Neurons from both E280A and Sporadic conditions compared to controls. Validation: Investigate selective modulators for specific neurotransmitter receptors (e.g., targeting AMPA or NMDA receptors to restore excitatory/inhibitory balance) or calcium channel blockers in neuronal AD models (e.g., organoids, transgenic mice) to assess their ability to restore synaptic function, reduce excitotoxicity, and mitigate neuronal cell death.

Follow-up validation ideas:

1. Perform spatial transcriptomics or proteomics to map the precise localization of altered cell-cell interactions and microglial states within AD brain regions, correlating findings with neuropathological hallmarks.
2. Utilize patient-derived iPSC-microglia and iPSC-neurons in co-culture models to functionally validate the impact of identified surface markers (e.g., ADGRE2, CD163, OLR1) on phagocytic activity, cytokine release, and neuronal viability under AD-like stress conditions.
3. Conduct *in vivo* studies using AD animal models (e.g., 5XFAD, APP/PS1) to test the therapeutic potential of modulating specific integrin pathways (e.g., via inhibitors) on blood-brain barrier integrity, neuroinflammation, and cognitive function.
4. Employ electrophysiology and super-resolution microscopy in AD mouse models or organoids to investigate the functional consequences of reduced Neurexin-Neuroligin and GABAergic interactions on synaptic plasticity and neuronal network activity.
5. Validate oligodendrocyte fatty acid elongation pathway dysregulation through targeted metabolomics and lipidomics in sorted oligodendrocytes from AD post-mortem brain tissue or animal models, followed by remyelination assays in relevant *in vitro* or *in vivo* systems.
6. Quantify the expression of specific microglial surfaceome markers (e.g., CX3CR1, DSCAM, CD163) using flow cytometry or immunostaining on larger cohorts of AD and control brain samples to confirm their diagnostic/prognostic biomarker potential.

Limitations:

This study is primarily descriptive and cross-sectional, limiting conclusions about causality or the temporal progression of observed changes. The assignment of 'disease' is inferred from dataset metadata, and while strongly supported, it relies on pre-existing classifications. Single-cell RNA sequencing provides valuable insight into cellular heterogeneity but loses spatial context crucial for understanding intercellular communication *in situ*. The presence of 'unassigned' cells in one E280A sample indicates potential biological or technical variability that warrants further investigation. Further, the analyses presented are based on pre-computed results, and a deeper exploration of individual gene expression changes within specific cell types could provide additional insights.

14. Query List

1. Show and save UMAPs including condition, sample, major cell type, minor cell type, and cell type subset, in 2 columns.
2. Show and save major cell type scores on UMAP.
3. Show and save a marker expression dot plot for cell type subset. Set target_cell to None and other arguments to default values.
4. Show and save a population bar plot for minor cell types.
5. Show and save a subset population bar plot for Microglia.
6. If there are significant differences between conditions in the Microglia subset population, show and save box plots. Set ncols appropriately based on the total number of panels.
7. Show and save cell-cell interactions by condition. Select up to 80 cell-cell interactions per condition.
8. Find and show a dot plot of statistically significant differences in cell-cell interactions between conditions for Microglia, Astrocytes, Endothelial cells, and Fibroblasts. Set max_n_items_per_group = 25 and save.
9. Extract and show a dot plot of condition-specific markers for Microglia. Show only surfaceome markers, up to 50 per condition, and save.
10. Extract and show a dot plot of condition-specific markers for Fibroblasts. Show only surfaceome markers, up to 50 per condition, and save.
11. Show and save a bar plot of Gene Ontology (GSA) analysis results for Neurons and Microglia.
12. Show and save a dot plot of Gene Set Enrichment Analysis results for Neurons, Oligodendrocytes, Astrocytes, and Microglia. Use 'RdBu_r' as the color map and set n_pws_to_show = 80.